Full patient enrolment in Phase IIa Menstrual Migraine study
Asarina Pharma AB (publ) (ASAP: FN Stockholm) has reached full patient enrolment in its Phase IIa menstrual migraine (MM) study. 158 women have been recruited… Read More »Full patient enrolment in Phase IIa Menstrual Migraine study